Version: 1.0.0 | Published: 8 Oct 2024 | Updated: 228 days ago
Documentation
Associated Media:
Description:
The Moorfields DMO Dataset encompasses all patients who have received at least one injection of either Lucentis (ranibizumab) or Eylea (aflibercept) to treat diabetic macular oedema (DMO) at Moorfields Eye Hospital - a leading provider of eye health services in the UK and a world-class centre of excellence for ophthalmic research and education.
These therapies began at Moorfields in 2013, however, the dataset will include any imaging or clinical metadata that is available for these patients prior to that time (for example in patients who were initially monitored for the early forms of the disease prior to receiving treatment). Also of note, this dataset will include data from both eyes in each case - for example, it will include data from fellow eyes that are not receiving injections. For these reasons, the dataset will include longitudinal data from a wide range of diabetic eye disease.
Clinical metadata includes information regarding:
- patient demographics
- visual acuities (predominantly measured with Early Treatment Diabetic Retinopathy Study (ETDRS) charts)
- diabetic retinopathy grading
- intravitreal therapies and ocular surgeries
Additional information is provided in the ‘technical details’ tab.
The DMO dataset includes eye imaging modalities, such as:
- Optical coherence tomography (CSO, Heidelberg, Optos, Topcon, Zeiss)
- Colour fundus photographs (Topcon, Zeiss)
- Ultra-wide field photographs (Optos, Zeiss)
- Iris photographs (CSO, Zeiss)
- Keratoscope topography (CSO)
- Infrared photographs (Heidelberg, Topcon, Zeiss)
- Fluorescein angiography (Heidelberg, Optos, Topcon, Zeiss)
- Indocyanine green angiography (Heidelberg, Optos, Topcon)
- Fundus autofluorescence (Heidelberg, Optos, Zeiss)
Imaging data from CSO is subject to additional approvals.
As of July 2024, the dataset consisted of 5,873 eyes receiving Lucentis or Eylea for DMO, over 58,808 injection episodes, and over 1,304,395 ophthalmic images. This is one of the largest single centre databases from patients with DMO and covers more than a decade of follow-up for these patients.
Coverage
Typical Age Range:
26-91
Follow Up:
> 10 Years
Pathway:
The dataset is representative of the entire pathway for patients receiving
treatment for diabetic macular oedema (DMO) in the Medical Retina service at
Moorfields Eye Hospital NHS Foundation Trust.
Provenance
Origin
Purposes:
Study
Collection Situations:
- Clinic
- Secondary care - Accident and Emergency
- Secondary care - Outpatients
- Secondary care - In-patients
Temporal
Accrual Periodicity:
Continuous
Start Date:
01 January 2003
Time Lag:
1-2 weeks
Accessibility
Access
Access Rights:
Access Service:
INSIGHT has established a Secure Research Environment (SRE) to provide
researchers with a computing environment that meets the security levels required
by regulation, with the power needed for analysis of large datasets. In addition
to the SRE, INSIGHT may provide approved researchers with alternative data
access methods, such as data egress, subject to meeting security conditions. For
more information please visit our SRE website
https://www.insight.hdrhub.org/secure-research-environment.
Access Request Cost:
Delivery Lead Time:
Not applicable
Jurisdictions:
GB-ENG
Data Controller:
Moorfields Eye Hospital NHS Foundation Trust
Usage
Data Use Limitations:
General research use
Data Use Requirements:
Project-specific restrictions
Resource Creators:
INSIGHT Health Data Hub
Format and Standards
Vocabulary Encoding Schemes:
- SNOMED CT
- DM+D
- NHS NATIONAL CODES
Languages:
en
Formats:
- csv
- image
Observations
Statistical Population
Population Description
Population Size
Measured Property
Observation Date
Persons
8,317 Eyes with 1,304,395 Images
5,873 Eyes with 58,808 Injections (Lucentis/Eylea)
4166
Patients
30 June 2024